0
0This scientific article from Cell Reports Medicine presents a new clinical framework for utilizing spatial transcriptomics to identify biomarkers in patients with muscle-invasive bladder cancer. The research focuses on the DUTRENEO trial, which categorizes tumors based on their inflammatory signatures to determine whether patients should receive immunotherapy or chemotherapy. By using advanced multi-omics characterization and Xenium in situ profiling, the authors mapped the tumor microenvironment at a cellular level to better predict treatment response. The study highlights various cell types, such as T-cells and fibroblasts, to illustrate how spatial data can be translated into practical medical oncology decisions. Ultimately, this work aims to improve patient outcomes by tailoring cancer therapies to the specific molecular architecture of an individual’s tumor.
References:
Grande E, Sibai M, Grases D, et al. Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study[J]. Cell Reports Medicine, 2026.
